Table 2.
Intracranial hyperthermia (HT) with immunotherapy (IT) clinical trials.
| Clinical trial indicator | HT method | IT agent | Population | Phase | Status |
|---|---|---|---|---|---|
| NCT03341806 | LITT | Avelumab | Adults with recurrent GBM | I | Recruiting |
| NCT04187872 | LITT | Pembrolizumab | Adults with recurrent brain metastases from primary melanoma, non-small cell lung cancer, or renal cell carcinoma | I | Not yet recruiting |
| NCT03277638 | LITT | Pembrolizumab | Adults with recurrent GBM | I/II | Recruiting |
| NCT03939975 | RFA | Pembrolizumab | Adults with advanced refractory hepatocellular carcinoma | II | Completed |
| NCT03993678 | LITT | N-dihydro-galactochitosan | Adults with advanced or recurrent solid tumors | I | Not yet recruiting |
GBM: glioblastoma; LITT: laser interstitial thermal therapy; RFA: radiofrequency ablation.